Cancer care: Long battle for affordable treatment

Cancer care: Long battle for affordable treatment Advances in oncology have improved treatment options, but their benefits remain out of reach for many patients who cannot afford to complete the prescribed course. This is despite the recent decision to cap trade margins on 137 identified non‑scheduled anti‑cancer medicines, providing some relief, writes Afshan Yasmeen, a senior policy analyst with the Health and Social Care Commission. The move, announced last month by the Department of Health and Social Care, aims to curb escalating drug costs that have strained NHS budgets and patients’ wallets alike..

Yet critics argue that the cap merely scratches the surface of a much larger affordability crisis that plagues modern cancer care across the UK. The cap limits the maximum margin that wholesalers can add to the price of each listed drug, a policy that mirrors similar measures introduced in Germany and France. By restricting how much extra can be added to the wholesale price, the government hopes to keep the final cost for patients lower..

However, the decision has been met with mixed reactions from industry stakeholders. Pharmaceutical companies contend that such caps could undermine research and development (R&D) investment, which they say is essential for continued breakthroughs in oncology. Industry insiders have long argued that the high cost of new drugs reflects the substantial expense of R&D, clinical trials, and regulatory approval..

They point out that the average time from discovery to market for a new drug can exceed a decade and cost upwards of €2 billion. “We are still in a period of rapid innovation,” says Dr. Emily Clarke, Chief Medical Officer at PharmaInnovate, who believes that capping trade margins may discourage investment in next‑generation therapies..

“Without the possibility of a premium return, companies risk losing the incentive to push forward with expensive trials.” Despite this, patient advocacy groups are hopeful that the cap could create a more level playing field. “The real issue is that patients are forced to choose between paying for treatment or missing out entirely,” says Maya Patel, director of the Cancer Support Alliance. Patel recalls the story of her brother, a 34‑year‑old engineer who had to skip a course of immunotherapy due to the prohibitive out‑of‑pocket cost..

“He is still fighting, but the financial burden has turned his fight into a nightmare,” she says, citing the growing prevalence of treatment abandonment as a direct result of high prices. The Department of Health and Social Care’s decision follows a comprehensive review of drug pricing that revealed a stark disparity between NHS and private-sector costs. The review found that, on average, the NHS paid 35 % more for the same anti‑cancer medicine than patients buying through private pharmacies..

By capping trade margins, the department hopes to reduce this differential, enabling the NHS to negotiate better bulk purchase prices and pass savings onto patients. “We are committed to ensuring that cost does not become a barrier to life‑saving treatment,” says Health ary Dr. Thomas Reeves in a statement to Parliament..

Financial experts warn that the cap may have unintended consequences if not paired with additional reforms. Professor David Lewis of the University of Leeds notes that the cap applies only to trade margins and does not directly affect manufacturer pricing. “If manufacturers set a high base price, capping the margin may not significantly lower the final price,” he explains..

He advocates for a complementary approach, such as value‑based pricing and outcome‑based contracts, where payments are tied to real-world effectiveness rather than upfront list prices. In response, the pharmaceutical industry has announced plans to explore alternative payment models. “We are ready to work with the NHS to develop outcome‑based agreements that can ensure patients receive effective treatments while managing cost,” says senior executive James Turner of Chemix Pharma..

Turner’s statement highlights a growing trend in the UK and elsewhere to negotiate discounts or rebates based on clinical outcomes. Such arrangements could provide a more flexible framework for balancing innovation and affordability. Meanwhile, patient communities are calling for increased transparency in drug pricing..

“People deserve to know why a drug costs what it does,” argues Lucy Evans, a cancer survivor and spokesperson for the Patient Voice Coalition. Evans points to the opaque nature of negotiations between drug companies and the NHS, where price concessions are often kept confidential. She calls for a publicly accessible database that would detail each drug’s list price, negotiated discount, and final NHS purchase price..

“Transparency would empower patients and policymakers to make informed decisions and drive fairer pricing,” Evans says. The government’s announcement also includes a provision for accelerated review of high‑cost drugs in light of the cap. The Department has set up a specialised task force that will evaluate each new anti‑cancer medicine within 90 days of approval to assess whether the cap is appropriate and to recommend adjustments if necessary..

“Our aim is to strike a balance between encouraging innovation and protecting patients from exorbitant costs,” says Dr. He adds that the task force will work closely with the Medicines and Healthcare products Regulatory Agency (MHRA) and the NHS England. Despite the optimism surrounding the trade‑margin cap, many experts caution that it will not solve the broader issue of drug affordability..

The UK’s National Institute for Health and Care Excellence (NICE) currently evaluates drugs on a cost‑effectiveness basis, often using a threshold of £20,000‑£30,000 per quality‑adjusted life year (QALY). Critics argue that the threshold itself is too high for many life‑saving treatments, especially those for rare cancers. “The pricing problem is systemic, involving R&D costs, market exclusivity, and the way value is measured,” notes Prof..

“A single policy is unlikely to address all these dimensions.” Patient stories continue to highlight the human cost of high drug prices..